| Literature DB >> 22510884 |
Michael Röring1, Ricarda Herr, Gina J Fiala, Katharina Heilmann, Sandra Braun, Anja E Eisenhardt, Sebastian Halbach, David Capper, Andreas von Deimling, Wolfgang W Schamel, Darren N Saunders, Tilman Brummer.
Abstract
The dimerisation of Raf kinases involves a central cluster within the kinase domain, the dimer interface (DIF). Yet, the importance of the DIF for the signalling potential of wild-type B-Raf (B-Raf(wt)) and its oncogenic counterparts remains unknown. Here, we show that the DIF plays a pivotal role for the activity of B-Raf(wt) and several of its gain-of-function (g-o-f) mutants. In contrast, the B-Raf(V600E), B-Raf(insT) and B-Raf(G469A) oncoproteins are remarkably resistant to mutations in the DIF. However, compared with B-Raf(wt), B-Raf(V600E) displays extended protomer contacts, increased homodimerisation and incorporation into larger protein complexes. In contrast, B-Raf(wt) and Raf-1(wt) mediated signalling triggered by oncogenic Ras as well as the paradoxical activation of Raf-1 by kinase-inactivated B-Raf require an intact DIF. Surprisingly, the B-Raf DIF is not required for dimerisation between Raf-1 and B-Raf, which was inactivated by the D594A mutation, sorafenib or PLX4720. This suggests that paradoxical MEK/ERK activation represents a two-step mechanism consisting of dimerisation and DIF-dependent transactivation. Our data further implicate the Raf DIF as a potential target against Ras-driven Raf-mediated (paradoxical) ERK activation.Entities:
Mesh:
Substances:
Year: 2012 PMID: 22510884 PMCID: PMC3365413 DOI: 10.1038/emboj.2012.100
Source DB: PubMed Journal: EMBO J ISSN: 0261-4189 Impact factor: 11.598